

Index

- abecarnil 310, 311, 312
 Abnormal Involuntary Movement Scale (AIMS)
 250–1, 259, 394
 acetaldehyde dehydrogenase 376
 acetazolamide 346
 adenosine deaminase acting on RNA (ADAR) 128,
 144–5
 aging influence on drug metabolism 168–9
 alcohol dehydrogenase 376
 alcoholism 28, 308
 alcohol dependence 374, 376, 377
OPRM1 alleles and 378
see also substance dependence
 allele refractory mutation system (ARMS) 423
 allele-specific amplification 423
 allele-specific hybridization 426
 allele-specific ligation 426–8
 α -adrenoceptors, clozapine response and 232–3
 Alzheimer's disease (AD) 78, 361–9
 amyloid precursor protein (APP) relationship
 405–6
 apolipoprotein E (ApoE) relationships 363–9,
 391–3, 407
 brain imaging studies 392–3, 395
 cholinergic treatments 363–7, 402
 noncholinergic treatments 367–9
 Alzheimer's Disease Assessment Scale–Cognition
 (ADAS-Cog) 361
 γ -aminobutyric acid *see* GABA
 amitriptyline 194–5
 AMPA receptors 138–9
 amphetamines 201
 amyloid precursor protein (APP), Alzheimer's
 disease relationship 405–6
 angiotensin 1-converting enzyme (ACE) 413
 animal studies 339–40
 benzodiazepine pharmacogenetics 343–4
 tardive dyskinesia 246–7
see also mouse models
 ANOVA 83
 anticonvulsant drugs (ACDs) 333–48
 bipolar disorder treatment 328
 genetic influences on pharmacology 335–47
 barbiturates 344–6
 benzodiazepines 342–4
 carbamazepine 340–1
 hydantoins 337–40
 valproic acid 341–2
see also specific drugs
 antidepressant drugs 283–4
 achiral antidepressants with chiral metabolites
 194
 chiral antidepressants 183–96
 drug response
 antidepressant-induced mania 290–4
 genetic predictors of 284–94
 heritability of 23–4
 pharmacogenetic differences 62–3
 serotonin transporter gene and 269–73,
 285–90
see also specific drugs
 antipsychotic drugs
 achiral drugs with chiral metabolites
 199–200
 chiral drugs 196–9
 heritability of drug response 24
see also specific drugs
 anxiety disorders 285, 300–1
 GABA-A receptor subunit role 307–8
 generalized anxiety disorder 285, 305
 apolipoprotein E (ApoE) 361–2
 Alzheimer's disease relationships 363–9, 391–3,
 407
 brain imaging studies 392–3, 395
 cholinergic treatments 363–7, 402
 noncholinergic treatments 367–9
 association studies 25–6, 74–5, 78–86, 406–8
 case-control design 25–6, 83
 limitations of 26–9, 74–5
 tardive dyskinesia 247–8
see also candidate gene approach
 asthma, candidate gene approach 25–6
 barbiturates 336, 344–6
 GABA-A receptor interactions 336, 344–5
see also specific drugs
 benign familial neonatal convulsions 346
 benzodiazepines (BDZs) 301, 302, 336, 342–4
 GABA-A receptor interactions 306–10, 336,
 343
 mechanism of action 302–3
see also specific drugs

440 Index

- bipolar disorder (BP) 287, 289, 320
 antidepressant-induced mania 291, 292–4
 response to mood stabilizers 328–9
see also lithium
- Bleuler, Eugen 44
- bovine spongiform encephalopathy 405
- brain development 105–7
 epistatic interaction relevance 115–17
 mouse models 107–11
 serotonin role 106–7, 108–11
- brain imaging 391–6
 Alzheimer's disease 392–3, 395
 schizophrenia 393–4, 395
 tardive dyskinesia 393–4, 395
- brain-derived neurotrophic factor (BDNF) 393
- Brief Psychiatric Rating Scale (BPRS) 221
- bupropion 194
- calcium channels 337
- candidate gene approach 9, 25–6
 limitations of case-control association studies 26–9
 lithium response 326–7
 manic-depressive illness 38–9
 sample size required 80–3
 schizophrenia 38–9
 study design 83–5
 tardive dyskinesia 247–8, 249–58
 dopaminergic receptors 248, 250–2
 metabolic enzymes 248, 256–8
 serotonergic genes 252–6
- carbamazepine 336, 340–1
 adverse effects 340
 bipolar disorder treatment 328–9
- case-control design 9–10, 25, 31, 74–5
 association studies 25–6, 83
 limitations of 26–9, 74–5
- catechol-*O*-methyltransferase (COMT) 275–6
- chi-square test 83
- chiral psychotropic drugs 181–203
 antidepressants 183–94
 achiral antidepressants with chiral metabolites 194–6
 recent antidepressants 193–4
 selective serotonin reuptake inhibitors 187–92
 tricyclic antidepressants 183–7
 antipsychotics 196–200
 achiral antipsychotics with chiral metabolites 199–200
 opioid substitutes 201–2
 stimulants and illicit drugs 201
 tranquilizers and hypnotic agents 200–1
- chiral switch 187–8
- chlorpromazine 157–8
- cholinergic muscarinic receptors, clozapine response and 232
- cigarette smoking *see* smoking
- citalopram 187–9
- citicoline 367–9
- Clinical Global Impression scale (CGI) 221, 286
- clomipramine, obsessive-compulsive disorder treatment 285–6
- clonazepam 336, 342
- clozapine 217–35, 248
 drug response 220–4
 criteria 220–2
 genetic predictors of 412, 414
 heritability of 24
 time taken for response 222
 genetic variation in receptors 222–34
 α -adrenoceptors 232–3
 cholinergic muscarinic receptors 232
 dopamine receptors 224–7
 epistatic interaction between genes 233–4
 GABA receptors 233
 histamine receptors 231
 serotonin receptors 227–31
 pharmacology 222–3
- cocaine dependence 373–4
 cocaine-induced paranoia as a phenotype 380–1
see also substance dependence
- CODE-system 47–8
- codeine 377
see also opioid dependence
- complex traits 119, 421
 drug responses as 96–7, 406, 420–1
 heritability 97
- Creutzfeldt–Jacob disease 405
- CYP enzymes 63, 65, 159–60
 intraindividual variability 166–70
 aging influence 168–9
 dietary influences 166–7
 disease influence 169–70
 drug–drug interactions 167
 nutraceutical influences 167–8
 nomenclature 159–60
 phenotyping/genotyping 409–10
 polymorphism 163
 tardive dyskinesia and 248
see also drug metabolism; *specific CYP enzymes*
- CYP1A2 257
 drug metabolism 185
 induction by smoking 173, 257
 polygenic control 164
 tardive dyskinesia and 257, 411
- CYP2A6 341
 nicotine dependence and 381–2
- CYP2B 341
- CYP2C9, drug metabolism 189, 190, 194, 202, 338, 341
- CYP2C19, drug metabolism 187–9, 193–4, 198, 202, 337–8, 342
- CYP2D6 164, 256
 drug metabolism 184–202
 phenotyping/genotyping 409–10
 polymorphism 160–2, 256, 377
 substance dependence and 377, 381–2
 tardive dyskinesia and 256
 tricyclic antidepressant toxicity and 63, 66–7, 69
- CYP3A4, drug metabolism 187–9, 194, 199–202, 340
- CYP4B 341
- cytochrome P-450 *see* CYP enzymes

441 Index

- DCR Budapest–Nashville classification system 46–7
- de Sauvages, Boissier 42
- deletion polymorphisms 8
- demographic variables 10
- denaturing high performance liquid chromatography (DHPLC) 426, 428–9
- dependence *see* substance dependence
- depressive illness
 delusional depression 270
 heterogeneity 39–40, 63–4
 major depression 40, 63, 285, 287–9
see also antidepressant drugs
- development, brain 105–7
 mouse models 107–11
 regulatory genes 111–12
 relevance of epistatic interactions 115–17
 serotonergic neuron specification and differentiation 112–15
- dexfenfluramine 201
- dextroamphetamine, heritability of drug response 24
- diabetes 78
- diagnostic instruments for research 46–8
 ADAS-Cog 363
 AIMS 50–1, 259
 BPRS 221
 CGI 221, 286
 CODE-system 47–8
 GAS 219
 DCR Budapest–Nashville 46–7
 MMSE 364
 PANSS 221, 251
 Y-BOCS 286
- diazepam 307, 338, 342, 344
- dietary influence on drug metabolism 166–7
- disease influence on drug metabolism 169–70
- DNA databases 408–9
- donepezil 366
- dopamine β -hydroxylase (DBH), cocaine dependence and 380–1
- dopamine receptors 248
 D₁ receptor, clozapine response and 224
 D₂ receptor 28, 29, 252
 aberrant alternative RNA splicing 135–7
 clozapine response and 224–5
 lithium response and 327–8
 tardive dyskinesia and 252
 D₃ receptor 250–2
 aberrant alternative RNA splicing 135–7
 clozapine response and 225–6
 tardive dyskinesia and 250–2, 394
 D₄ receptor 27, 29, 115–16
 clozapine response and 226–7
 D₅ receptor, clozapine response and 224
 role in schizophrenia 250–1
- dopaminergic enzymes 248
- drug dependence *see* substance dependence
- drug development 401–15
 genomics application 403–6
 pharmacogenetic differences and 61–5
 pharmacogenetics and drug toxicity 411–12
 phenotyping/genotyping drug metabolism 409–11
 polymorphism application 406–8
 predictors of drug response 412–14
 prospective enrichment of trials through genotyping 414–15
- drug efficacy 67–9, 220
 poor signal:noise ratio 60–1, 64
see also drug response; therapeutic drug monitoring
- drug metabolizing enzymes (DMEs) 158, 171, 409
 genetic variability 160–4
 relevance for study design 164–5
see also CYP enzymes
- drug metabolism 157, 158
 genetic variability 160–4, 170–1
 CYP1A2 regulation 164
 CYP2D6 polymorphism 160–2
 intraindividual variations 165–70
 aging influence 168–9
 dietary influences 166–7
 disease influence 169–70
 drug–drug interactions 167
 nutraceutical influences 167–8
 phase I and phase II metabolism 158–9
 phenotyping/genotyping 409–11
see also specific drugs
- drug response 57–8, 158
 as a complex trait 96–7, 406, 420–1
 genetic variability and 335
 heritability of 22–4
 antidepressants 23–4
 antipsychotics 24
 influences 221–2
 medicine response profiling 383
 methodological issues 24–6
 pharmacogenetic differences 59–60
 drug development and 61–5
 existing drugs and 65
 phenotype definition 76–8
 responder/nonresponder phenotype 76–7
 side effect phenotype 77–8, 219–20
 tardive dyskinesia 248–9
 predictors of 284–94, 412–14
see also drug efficacy; drug metabolism; *specific drugs*; therapeutic drug monitoring
- drug toxicity 77–8, 219–20
 carbamazepine 340
 extrapyramidal side effects 219
 pharmacogenetics and 411–12
 surrogate markers 68–9
 tricyclic antidepressants 68–9
 CYP2D6 role 63, 66–7, 69
 surrogate markers 68–9
see also tardive dyskinesia
- drug–drug interactions 167
- dye-labeled oligonucleotide ligation (DOL) 430
- dystonia 246
- Ecstasy (MDMA) 203
 efficacy *see* drug efficacy

442 Index

- electrophoresis 428
 epidemiological genetics 37
 epilepsy 311, 333
 benign familial neonatal convulsions 346
 see also anticonvulsant drugs
 epistasis 9, 11
 clozapine response and 233–4
 relevance to brain development 115–17
 Esquirol, Jean-Etienne Dominique 42
 ethanol metabolism 376
 see also alcoholism
 ethnic diversity 10, 29, 338
 drug toxicity 411
 genomic control method 31
 nicotine metabolism 382
 Eve (MDE) 203
 exonic splicing enhancers (ESEs) 137
 exonic splicing suppressors (ESSs) 137
 5' exonuclease assay 429–30
 extrapyramidal side effects (EPS) 219
 see also tardive dyskinesia
- family studies 406–7
 see also twin studies
 felbamate 346
 flumazenil 307, 311
 flunitrazepam 307
 fluorescence energy resonance transfer (FRET)
 428, 429
 fluorescence polarization 429
 fluorodeoxyglucose (FDG) imaging, schizophrenia
 394
 fluoxetine 189–92
 flurazepam 338
 fluvoxamine, drug response
 COMT polymorphism and 276
 heritability 23
 pindolol augmentation 270–2, 288–9
 serotonin transporter gene linked
 polymorphic region (5-HTTLPR) and
 269–71, 287–9
- functional magnetic resonance imaging (fMRI),
 Alzheimer's disease 392
- GABA 133, 300
 GABA receptors 302, 343
 GABA-A receptor 133–4, 302–13
 aberrant alternative splicing 134
 barbiturate interactions 336, 344–5
 benzodiazepine interactions 306–10, 336,
 343
 clozapine response and 233
 drug development 311–12
 mutation studies 308–9
 neurosteroids and 312
 possible interventions 309–11
 role in anxiety 307–8
 subunit functions 306–7
 gabapentin 346
 galantamine 366
 gamma-aminobutyric acid *see* GABA
 ganaxoxone 312
- GATA3 transcription factor 114
 gene expression 12, 96
 pharmacodynamic factors 98–100
 regulation 96, 98
 gene–environment interactions 165–6
 clozapine response and 232–4
 relevance to brain development 115–17
 gene–gene interactions 11, 86, 115
 see also complex traits
 generalized anxiety disorder 285, 305
 genetic variation
 drug responsiveness and 335
 nature of 334
 see also polymorphism
 genomic control method 31, 83
 genomics 433
 application to drug development 403–6
 see also pharmacogenomics
- genotyping
 allele detection 428–9
 denaturing high performance liquid
 chromatography (DHPLC) 428–9
 electrophoresis 428
 fluorescence polarization 429
 fluorescence resonance energy transfer
 429
 labeling the amplified product 428
 MALDI-TOF mass spectrometry 429
 molecular conformation 428
 allele discrimination 423–8
 allele-specific amplification 423
 allele-specific hybridization 426
 allele-specific ligation 426–8
 heteroduplex/homoduplex resolution 426
 primer extension and minisequencing 426
 restriction endonuclease digestion 423
 drug metabolism 409–11
 highly specialized probes 429–31
 dye-labeled oligonucleotide ligation 430
 molecular beacons 430
 peptide nucleic acid hybridization probes
 430–1
 TaqMan (5' exonuclease assay) 429–30
 template-directed dye incorporation 430
 Invader assay 431
 kinetic polymerase chain reaction 433
 ligase chain reaction 431
 light-up probes 431
 padlock probes 431
 prospective enrichment of drug trials 414–15
 realtime polymerase chain reaction 432
- Gli2 transcription factor 113
 Global Assessment Scale (GAS) 221
 glutamate receptors, RNA transcript editing
 alterations 138–41
 glutathione S-transferase 411
 growth factors 114
- haloperidol 199, 247
 brain imaging studies 394
 haplotypes 28, 85
 Heinrichs–Carpenter scale 221

443 Index

- heritability
 complex traits 97
 drug response 22–4
 antidepressants 23–4
 antipsychotics 24
 lithium 321–5
 manic-depressive illness 37, 38–9
 mathematical models of inheritance 38
 schizophrenia 37, 38–9
 substance dependence 374
 heteroduplex/homoduplex resolution 426
 hexobarbital 345
 histamine receptors, clozapine response and 231
 5-HT *see* serotonin
 5-HTTLPR *see* serotonin linked polymorphic region
 Human Genome Project 30
 human leukocyte antigen (HLA), tardive dyskinesia and 246
 hydantoins 337–40
Hypericum perforatum (St. John's wort) 167–8

 identity by descent (IBD) 406–7
 imidazenil 310
 imipramine, heritability of drug response 23
 infection influence on drug metabolism 169
 inflammation influence on drug metabolism 169
 inheritance *see* heritability
 inositol polyphosphate 1-phosphatase 328
 insertion polymorphisms 8
 Invader assay 431

 Kahlbaum, Karl 42–3
 kainate receptors 138–9
 kinetic polymerase chain reaction (PCR) 433
 Kleist, Karl 44–5
 Kraepelin, Emil 43–4

 labeling 428
 Lehman Quality of Life Interview 221
 Leonhard, Karl 45
 ligase chain reaction 431
 light-up probes 431
 linkage analysis 24–5, 406–7
 lithium response 327
 manic-depressive illness 38
 schizophrenia 38
 linkage disequilibrium (LD) 9, 74, 81, 83–5
 lithium 157–8, 320, 410
 drug response 320–8
 as a phenotype 325–6
 family and family-history studies 321–5
 mode of inheritance 325
 studies comparing responders and nonresponders 327–8
 studies of responders as a homogenous subtype 326–7
 liver disease influence on drug metabolism 169–70

 major depression 40, 63, 285, 287–9
 MALDI-TOF mass spectrometry 429

 manganese superoxide dismutase (MnSOD), tardive dyskinesia and 257–8
 mania, antidepressant-induced 290–4
 epidemiology 290–1
 pharmacogenetics 291–2
 manic-depressive illness, heritability 37, 38–9
 candidate gene approach 38–9
 linkage analysis 38
 Mantel–Haenszel test 83
 mass spectrometry 426, 429
 MDE (Eve) 203
 MDMA (Ecstasy) 203
 medicine response profiling 383
 mephenytoin 337–8
 mephobarbital 344, 345
 methadone 201–2
 N-methyl-D-aspartate (NMDA) receptor 131
 aberrant alternative splicing of NR1 subunit 132–3
 role in schizophrenia 131–3
 metrifonate, Alzheimer's disease treatment 363–5
 mianserin 183–5
 microsatellites 9
 midazolam 342, 343
 milnacipran 193
 Mini-Mental Status Examination (MMSE) 364
 minisatellites *see* variable number tandem repeats (VNTRs)
 minisequencing 426
 mirtazapine 185–6
 missense mutations 334
 molecular beacons 430
 molecular conformation 428
 monoamine oxidase (MAO) 273–4
 citalopram metabolism 187–9
 MAO-A 104–5
 Parkinson's disease and 274–5
 monoamine oxidase inhibitors (MAOIs) 284
 mood stabilizers, response to 328–9
 see also lithium
 mouse models
 brain development 107–11
 GABA-A receptor subunit role in anxiety 307–8
 RNA transcript editing alterations 139–40
 see also animal studies
 multifactorial traits 9

 naltrexone 377
 neuropsychopharmacology 41
 neurosteroids 312
 neurotrophins 113–15, 116
 nicotine metabolism 382
 see also smoking
 NNDA receptor 131
 norfluoxetine 190–2
 nortriptyline 194–6
 nosological matrix 48–50
 nosology *see* psychiatric nosology
 nutraceutical influences on drug metabolism 167–8

444 Index

- obsessive-compulsive disorder (OCD) 285
 antidepressant response 272
 comorbid tic disorder and 286–7
 serotonin transporter gene and 285–7
 olanzapine 402
 oligonucleotide ligation assay (OLA) 426–8
 opioid dependence 373, 375, 377–80
 CYP2D6 and 377
 receptor/ligand interactions 377–80
 see also substance dependence
 opioid receptor *OPRM1* alleles 377–80
 polymorphisms 378–80
 oxazepam 200
- P-450 *see* CYP enzymes
 padlock probes 431
 panic disorder 285
 Parkinson's disease (PD) 246
 MAO-A polymorphism and 274–5
 SSRI response 272–3
 paroxetine response, serotonin transporter gene
 linked polymorphic region (5-HTTLPR)
 and 269–71, 287
 peptide nucleic acid (PNA) hybridization probes
 430–1
 Pet1 transcription factor 113–14
 pharmacodynamics 8, 96
 pharmacogenetics 6, 72–3, 218, 360–1
 definition of terms 6–8
 drug development and 61–5
 historical perspective 5–6
 pharmacogenetic traits 73–6
 research *see* research design
 see also pharmacogenomics;
 psychopharmacogenetics
 pharmacogenomics 6–7, 73, 421, 433
 see also genomics; pharmacogenetics
 pharmacokinetics 8
 phenobarbital 336, 340, 344, 345–6
 phenotype
 alternative phenotypes 40–1, 290
 definition and evaluation 10, 76–8
 responder/nonresponder phenotype 76–7
 side effect phenotype 77–8
 tardive dyskinesia 248–9
 see also drug response
 phenytoin 336, 338–40
 phospholipase C 326
 pindolol, SSRI treatment augmentation 270–2,
 288–9
 Pinel, Philippe 42
 polygenic traits 9
 polymerase chain reaction (PCR) 423
 kinetic PCR 433
 realtime PCR 432
 polymorphism 8–9, 79–80, 97
 application to drug development 406–9
 deletion polymorphisms 8
 insertion polymorphisms 8
 predictors of drug response 412–14
 regulatory genes 98–100
 simple tandem repeats (STRs) 9
 variable number tandem repeats (VNTRs) 8–9
 see also single nucleotide polymorphisms *specific
 polymorphic molecules*
 population effects 10
 Positive and Negative Symptom Scale (PANSS)
 221, 251
 positron emission tomography (PET), Alzheimer's
 disease 392–3
 post-transcriptional RNA processing *see* RNA
 processing
 primer extension 426
 progesterone 312
 proteomics 403, 405
 psychiatric nosology 41–6
 Bleuler, Eugen 44
 de Sauvages, Boissier 42
 Esquirol, Jean-Etienne Dominique 42
 Kahlbaum, Karl 42–3
 Kleist, Karl 44–5
 Kraepelin, Emil 43–4
 Leonhard, Karl 45
 nosological matrix 48–50
 Pinel, Philippe 42
 Schneider, Kurt 45–6
 Wernicke, Carl 44
 psychopharmacogenetics 95–6
 phenotype definition 76–8
 responder/nonresponder phenotype 76–7
 side effect phenotype 77–8
 rationale for 4–5
 see also drug response; pharmacogenetics
 quantitative trait loci (QTL) 96, 98, 247, 249
 QTL mapping 339
- realtime polymerase chain reaction 432
 reboxetine 194
 research design issues 9–12
 demographic variables 10
 gene expression 12
 interaction among multiple loci 11, 86
 phenotype definition and evaluation 10
 population effects 10
 see also study design
 restriction endonuclease digestion 423
 retigabine 346
 risperidone 200, 402
 RNA processing 128–9
 aberrant alternative splicing in psychiatric
 disorders 131–8
 dopamine D₂ and D₃ receptors 135–7
 GABA-A receptor 133–4
 mechanisms 137–8
 NMDA receptor NR1 subunit 131–3
 editing alterations implicated in psychiatric
 disorders 138–45
 glutamate receptors 138–41
 mechanisms 143–5
 serotonin 2C receptor 141–3
- S12024 367
 St. John's wort (*Hypericum perforatum*) 167–8

445 Index

- salbutamol 26
- schizophrenia
 alternative phenotypes 40–1
 brain imaging studies 393–4, 395
 dopamine D₃ receptor role 250–1
 heritability 37, 38–9
 candidate gene approach 38–9
 linkage analysis 38
 RNA processing and
 GABA-1 receptor 134
 NMDA receptor 131–3
see also tardive dyskinesia
- Schneider, Kurt 45–6
- scorpion primers 430
- selective serotonin reuptake inhibitors (SSRIs)
 255–6, 284, 285, 402
 anxiety treatment 302
 chiral drugs 181–94, 196–9, 200–2
 drug response
 comorbid tic disorder and 286–7
 obsessive-compulsive disorder 285–7
 serotonin transporter gene linked
 polymorphic region (5-HTTLPR) and
 269–73, 285–9
 Parkinson's disease treatment 272–3
 pindolol augmentation 270–2, 288–9
see also antidepressant drugs; *specific drugs*
- serotonin (5-HT) 284
 role in brain development 105–7, 108–11
 serotonergic neuron developmental specification
 and differentiation 112–15
- serotonin receptors
 5-HT_{1A} receptor, clozapine response and 227
 5-HT_{2A} receptor 252
 clozapine response and 228–9
 tardive dyskinesia and 252–4
 5-HT_{2C} receptor 141, 254
 clozapine response and 228–9
 RNA transcript editing alterations 141–3
 tardive dyskinesia and 254–5
 5-HT₃ receptor, clozapine response and 229–30
 5-HT_{5A} receptor, clozapine response and 230
 5-HT₆ receptor, clozapine response and 230
 5-HT₇ receptor, clozapine response and 231
 genomic variants 100–2
- serotonin reuptake inhibitors (SRIs)
 obsessive-compulsive disorder treatment 272
see also selective serotonin reuptake inhibitors
 (SSRIs)
- serotonin transporter (5-HTT) 269, 285
 antiobsessional response and 285–7
 clozapine response and 231
 genomic variants 102–4, 116–17
 lithium response and 328
 tardive dyskinesia and 255–6
 variable number of tandem repeats 283
 serotonin linked polymorphic region 5-HTTLPR
 256, 269–73, 285
 antidepressant response and 269–73, 285–90
 role in antidepressant-induced mania 291–4
- side effects *see* drug toxicity
- signal:noise ratio, drug efficacy trials 60–1, 64
- silent mutations 334
- simple tandem repeats (STRs) 9
- single nucleotide polymorphisms (SNPs) 8, 79–80,
 118, 278, 334, 408, 433–4
 frequency of 79
 genotyping technology 32, 422–33
 allele detection 428–9
 allele discrimination 423–8
 highly specialized probes 429–31
 non-PCR based strategies 431–3
 identification of 12, 30, 383–4
 interactions among multiple loci 11
 properties of 422
 role in pharmacogenomic research 422
 sample size required for candidate gene studies
 80–3
- SLC6A4* gene 285, 289
see also serotonin transporter (5-HTT)
- smoking
 CYP1A2 induction 173, 257
 nicotine dependence 373–5
 CYP enzymes and 381–2
see also substance dependence
- SNPs *see* single nucleotide polymorphisms
- sodium channels 336
- spliceosome 129
- splicing *see* RNA processing
- statistical approaches
 gene interactions 86
 methodological developments 31
 pharmacogenetic traits 73–6
 sample size required for candidate gene studies
 80–3
 study design 83–5
- stereoselective drugs *see* chiral psychotropic
 drugs
- study design 11, 83–5
 case-control design 9–10, 25, 31, 74–5
 association studies 25–9, 83
 limitations of 26–9, 74–5
 developments in statistical methodologies 31
 linkage analysis 24–5
see also research design issues
- substance dependence
 genetics of 373–5
 heritability 374
 pharmacodynamic effects 375–6
 pharmacogenetics 376–83
 cocaine dependence 380–1
 opioid dependence 377–80
 tobacco dependence 381–2
 pharmacokinetic effects 376
- substance P 413–14
- sulpiride 199
- sunrise probes 430
- t-test 83
- tacrine
 Alzheimer's disease treatment 363, 365–6
 toxicity 411
- Taq A1* allele 28, 29
- TaqMan (5' exonuclease assay) 429–30

446 **Index**

- tardive dyskinesia (TD) 245–61, 411
 additive small gene effects 258
 brain imaging studies 393–4, 395
 candidate gene studies 247–8, 249–58
 dopaminergic enzymes and receptors 248, 250–2, 394
 metabolic enzymes 248, 256–8
 serotonergic genes 252–6
 evidence for genetic basis 245–6
 animal data 246–7
 phenotype definition 248–9
 template-directed dye incorporation (TDI) 430
 terfenadine 411
 therapeutic drug monitoring (TDM) 67–9, 171
 tricyclic antidepressants 66–7
 thiopurine toxicity 411
 thioridazine 196–8
 tic disorder comorbidity with obsessive-compulsive disorder 286–7
 tobacco dependence *see* smoking
 total sleep deprivation (TSD) 273, 287
 Tourette syndrome comorbidity with obsessive-compulsive disorder 286–7
 toxicity *see* drug toxicity
 transcription factors 112
 see also specific factors
 transcriptional profiling 405
 transmission disequilibrium test (TDT) 75
 triazolopyridazine 311
 tricyclic antidepressants (TCAs) 283–4
 chiral drugs 183–7
 pharmacogenetic differences in response 62–3
 therapeutic drug monitoring 66–7
 toxicity 68–9
 CYP2D6 role 63, 66–7, 69
 surrogate markers 68–9
 see also antidepressant drugs; *specific drugs*
 trimipramine 186–7
 tropicamide 366–7
 twin studies
 heritability of drug response 22–3, 24
 manic-depressive illness 37
 schizophrenia 37
 substance dependence 374
 tyrosine hydroxylase 326, 327
 valproic acid 336–7, 340, 341–2
 bipolar disorder treatment 328
 variable number tandem repeats (VNTRs) 8–9
 serotonin transporter gene 285
 venlafaxine 193–4
 viloxazine 194
 warfarin 411
 Wernicke, Carl 44
 WHOQOL-100 221
 xanomeline 367
 Yale–Brown Obsessive-Compulsive Scale (Y-BOCS) 286
 zolpidem 310, 311–12, 343
 zopiclone 201, 310